Biosimilars | Association for Accessible Medicines

AAM Commends Introduction of the Increasing Access to Biosimilars Act

WASHINGTON, DC (July 2, 2020) — AAM and its Biosimilars Council commend Senators Cornyn and Bennet for introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest-cost medicine. Biosimilars consistently deliver savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers.

Read more about AAM Commends Introduction of the Increasing Access to Biosimilars Act

AAM Files Amicus Brief Supporting the BPCIA

WASHINGTON, DC (May 14, 2020) — The Association for Accessible Medicines (AAM) has filed an amicus brief in the latest constitutional challenge to the Affordable Care Act (ACA), arguing that even if the individual mandate of the ACA is deemed unconstitutional, the biosimilars pathway (BPCIA) should survive.

Read more about AAM Files Amicus Brief Supporting the BPCIA

Top 10 Ways to Commemorate the 10th Anniversary of Biosimilars in the U.S.

U.S. biosimilar medicines are 10 years old this month. It’s been an amazing journey so far, and we see great promise and opportunity ahead, with greater access and lower prices for patients with cancer, Crohn’s disease, rheumatoid arthritis and other conditions. Here are 10 ways to mark this auspicious anniversary:

10. Learn more about the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) at www.b10similars.org.

Read more about Top 10 Ways to Commemorate the 10th Anniversary of Biosimilars in the U.S.

USMCA: Nothing to See Here (Infographic)

Brand-name drug companies claim that without USMCA, there's no market for biologics in Mexico. But, the world's largest pharmaceutical companies launched their top-selling biologics in Mexico. Learn more in this infographic:

Read more about USMCA: Nothing to See Here (Infographic)

Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA

The pharmaceutical provisions included in the negotiated text of the U.S.-Mexico-Canada Agreement will do many things. But creating a market for biologics in Mexico is not one of them. Why? Because pharmaceutical companies have been selling original biologics in Mexico since before 2001.

Read more about Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA

White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access and savings by providing competition for costly brand-name biologics.

Read more about White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Submitted by eklinger on Mon, 09/09/2019 - 11:14

Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.

The conference legal track:

Read more about AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

AAM's Christine Simmon Talks About Biosimilar Programming at GRx+Biosims 2019

Submitted by eklinger on Fri, 07/19/2019 - 11:17

I’m Christine Simmon, Senior Vice President of Policy and Executive Director of the Biosimilars Council at the Association for Accessible Medicines.

Working in this sector, I know how it feels to be inundated with invites to conferences and seminars and workshops and webinars -- all of which are supposed to help you stay on top of biosimilars. It’s a lot!

Read more about AAM's Christine Simmon Talks About Biosimilar Programming at GRx+Biosims 2019

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.

Read more about The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients

As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars are lower-priced versions of brand medicines used to treat debilitating and life-threatening diseases, such as Crohn’s disease, ulcerative colitis, cancer and psoriatic arthritis. Patients and physicians can rely on FDA-approved biosimilar medicines just as they would the brand-name product.

Read more about White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients

Subscribe to Biosimilars